

GLAXOSMITHKLINE PLC  
Form 6-K  
September 10, 2015

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending September 2015

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

GlaxoSmithKline plc

Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons

In accordance with DTR 3.1.4R(1)(a) GlaxoSmithKline plc ('GSK') was advised on 10 September 2015 that the following Directors and Persons Discharging Managerial Responsibilities ('PDMR') acquired GSK Ordinary Shares ('Shares') on 9 September 2015, at a price of 1317.69 pence per Ordinary Share, through GSK's ShareReward Plan (the 'Plan'):

Director/PDMR	Number of Shares under the personal contribution element of the Plan	Number of Shares under the matching contribution element of the Plan (GSK contribution)
Sir Andrew Witty	10	10
Mr R G Connor	10	10
Mr S Dingemans	10	10
Mr N Hirons	10	10
Mr D S Redfern	10	10
Ms C Thomas	10	10
Mr P C Thomson	9	9
Dr P J T Vallance	10	10
Ms E Walmsley	10	10
Mrs V A Whyte	10	10

V A Whyte  
Company Secretary

10 September 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: September 10, 2015

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc